Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Hitesh Mistry

The University of Manchester

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Pharmacotherapy

80%

Radiology

40%

Oncology

80%

Cancer Biology

70%

Radiation Therapy

50%

Dose Optimization

50%

Cancer Therapy

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles25

The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma

Article Link

Year:

2025

KDM6A, ARID1A and SETD2 loss-of-function mutations as prognostic biomarkers and their association with sites of metastatic progression in locally-advanced, recurrent or metastatic adenoid cystic carcinoma

Article Link

Year:

2025

A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors

Article Link

Year:

2025

A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

Article Link

Year:

2025

Machine Learning and Artificial Intelligence in <scp>PK‐PD</scp> Modeling: Fad, Friend, or Foe?

Article Link

Year:

2024

Tale of two zones: investigating the clinical outcomes and research gaps in peripheral and transition zone prostate cancer through a systematic review and meta-analysis

Article Link

Year:

2024

Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD)

Article Link

Year:

2024

A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE in patients with lung cancer

Article Link

Year:

2024

Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model

Article Link

Year:

2024

Tumour Size and Overall Survival in a Cohort of Patients with Unifocal Glioblastoma: A Uni- and Multivariable Prognostic Modelling and Resampling Study

Article Link

Year:

2024

A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial

Article Link

Year:

2024

Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small-cell lung cancer: a brief report from the CONVERT trial

Article Link

Year:

2024

Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancer.

Article Link

Year:

2024

Hypoxia-associated gene signatures are not prognostic in high-risk localised prostate cancers undergoing androgen deprivation therapy with radiotherapy

Article Link

Year:

2024

Training and external validation of pre-treatment FDG PET-CT-based models for outcome prediction in anal squamous cell carcinoma

Article Link

Year:

2024

Association between radiotherapy protocol variations and outcome in the CONVERT trial

Article Link

Year:

2023

Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer

Article Link

Year:

2023

Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway

Article Link

Year:

2023

Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma

Article Link

Year:

2023

Radiosensitivity Index (“RSI”) is not fit to be used for dose-adjustments: a pan-cancer analysis

Article Link

Year:

2023

Skipping a pillar does not make for strong foundations: Pharmacokinetic‐pharmacodynamic reasoning behind the shape of dose–response relationships in oncology

Article Link

Year:

2023

Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer

Article Link

Year:

2022

Determining bioequivalence possibilities of long acting injectables through population PK modelling

Article Link

Year:

2022

Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy

Article Link

Year:

2022

Clinico-pathological predictors of clinical complete response in rectal cancer

Article Link

Year:

2022

Collaborators18

Frank Kloprogge

UNITED KINGDOM

Tim Smith

Senior Lecturer

Bangor University

UNITED KINGDOM

Tim Illidge

The University of Manchester

UNITED KINGDOM

Fiona Blackhall

The University of Manchester

UNITED KINGDOM

Parmesh Gajjar

Chief Technology Officer

Infex Therapeutics

UNITED KINGDOM

Peter Hoskin

The University of Manchester

UNITED KINGDOM

Esther Baena

The University of Manchester

UNITED KINGDOM

James O'Connor

Professor and Team Leader

Institute of Cancer Research

UNITED KINGDOM

Robert Bristow

The University of Manchester

UNITED KINGDOM

Ann Henry

Associate Professor in Clinical Oncology

University of Leeds School of Medicine

UNITED KINGDOM

robert metcalf

The University of Manchester

UNITED KINGDOM

Kayode Ogungbenro

Lecturer

The University of Manchester

UNITED KINGDOM

Ananya Choudhury

The University of Manchester

UNITED KINGDOM

Corinne Faivre-Finn

The University of Manchester

UNITED KINGDOM

David Woolf

Honorary Senior Lecturer

University of Manchester

UNITED KINGDOM

Catharine West

The University of Manchester

UNITED KINGDOM

Leon Aarons

The University of Manchester

UNITED KINGDOM

Lee Malcomson

The University of Manchester

UNITED KINGDOM

How do I reach out?

Meet Kite AI